Avanos Medical (AVNS) Depreciation & Amortization (CF) (2013 - 2026)

Avanos Medical has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $10.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 6.25% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (down 9.61% YoY) and the FY2025 annual result came in at $38.9 million, down 14.51% from the prior year.
• Depreciation & Amortization (CF) climbed to $10.2 million in Q1 2026 per AVNS's latest filing, from $9.9 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $13.4 million in Q4 2022 and troughed at $9.4 million in Q3 2025.
• A 5-year average of $11.1 million and a median of $11.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 41.05% in 2022, then dropped 19.66% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $13.4 million in 2022, then declined by 14.18% to $11.5 million in 2023, then retreated by 3.48% to $11.1 million in 2024, then fell by 10.81% to $9.9 million in 2025, then gained by 3.03% to $10.2 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $10.2 million, $9.9 million, and $9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.